

From: Uma Everett <UEVERETT@sternekessler.com>
Sent: Wednesday, January 16, 2019 3:12 PM
To: Daniel Wiesner; JC Rozendaal; Michael Joffre; Will Milliken
Cc: Nick Cerrito; Eric Stops; John Galanek; Liza Walsh (LWalsh@walsh.law); Eleonore Ofosu-Antwi (EOfosuantwi@walsh.law); clizza@saul.com; Moses, David L. <dmoses@saul.com>; Sarah Sullivan; Slavin, Elina; WBaton@saul.com
Subject: RE: Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. et al., No. 18-3632 (D.N.J.)

Nick,

We have further considered your scheduling proposal in exchange for bifurcating Teva's patent misuse defense. As you know, Teva's ANDA product has received tentative approval, and the only thing preventing Teva's launch at the end of February 2019 is the 30-month stay based on Corcept's meritless lawsuit. Therefore, Teva cannot agree to a schedule that extends resolution of the asserted patents beyond the 30-month stay (i.e., August 2020). In addition, Teva does not consent to the addition of any additional patent to this litigation, particularly if the addition would result in delay of the trial. It thus appears that the parties cannot reach resolution and will need to submit competing schedules to the Court in advance of our February 11th Rule 16 conference. Under the circumstances, we cannot agree to bifurcate Teva's patent misuse defense.

Regards,
Uma

Uma Everett
Director
Sterne, Kessler, Goldstein & Fox P.L.L.C.
Email: ueverett@sternekessler.com
Direct: 202.772.8520

Administrative Assistant: Chelsea Santiago
Direct: 202.772.8894 **Main:** 202.371.2600

From: Daniel Wiesner [mailto:danielwiesner@quinnemanuel.com]
Sent: Monday, January 14, 2019 12:51 PM
To: Uma Everett; JC Rozendaal; Michael Joffre; Will Milliken
Cc: Nick Cerrito; Eric Stops; John Galanek; Liza Walsh (LWalsh@walsh.law); Eleonore Ofosu-Antwi (EOfosuantwi@walsh.law); clizza@saul.com; Moses, David L. <dmoses@saul.com>; Sarah Sullivan; Slavin, Elina; WBaton@saul.com
Subject: RE: Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. et al., No. 18-3632 (D.N.J.)

Yes, that works. We can use the below dial-in:

Tel: 866-499-9580
Code: 9080950

Thanks,
Dan

From: Uma Everett [<mailto:UEVERETT@sternekessler.com>]
Sent: Monday, January 14, 2019 10:56 AM
To: Daniel Wiesner <danielwiesner@quinnemanuel.com>; JC Rozendaal <JCROZENDAAL@sternekessler.com>; Michael Joffre <MJOFFRE@sternekessler.com>; Will Milliken <WMilliken@sternekessler.com>
Cc: Nick Cerrito <nickcerrito@quinnemanuel.com>; Eric Stops <ericstops@quinnemanuel.com>; John Galanek <johngalanek@quinnemanuel.com>; Liza Walsh (LWalsh@walsh.law) <LWalsh@walsh.law>; Eleonore Ofosu-Antwi (EOfosuantwi@walsh.law) <EOfosuantwi@walsh.law>; clizza@saoul.com; Moses, David L. <dmoses@saoul.com> <dmoses@saoul.com>; Sarah Sullivan <Sarah.Sullivan@saoul.com>; Slavin, Elina <Elina.Slavin@saoul.com>; WBaton@saoul.com
Subject: RE: Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. et al., No. 18-3632 (D.N.J.)

Dan,

We are available to speak on Tuesday at 4:30 p.m. Does that work for your team?

Regards,
Uma

From: Daniel Wiesner [<mailto:danielwiesner@quinnemanuel.com>]
Sent: Friday, January 11, 2019 5:00 PM
To: Uma Everett; JC Rozendaal; Michael Joffre; Will Milliken
Cc: Nick Cerrito; Eric Stops; John Galanek; Liza Walsh (LWalsh@walsh.law); Eleonore Ofosu-Antwi (EOfosuantwi@walsh.law); clizza@saoul.com; Moses, David L. <dmoses@saoul.com>; Sarah Sullivan; Slavin, Elina; WBaton@saoul.com
Subject: RE: Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. et al., No. 18-3632 (D.N.J.)

Uma,

Thank you for your email. Corcept's scheduling proposal is attached. As your team suggested during the call last week, Corcept's proposed schedule accounts for adding to the case relevant patents that have either recently issued or recently been granted a notice of allowance.

It would probably make sense to arrange another call for next week to discuss the schedule. We are generally available Tuesday afternoon; please let us know if there is a time that works for your team.

Regards,
Dan

Daniel Wiesner
Of Counsel
Quinn Emanuel Urquhart & Sullivan, LLP

51 Madison Avenue, 22nd Floor
New York, NY 10010
212-849-7560 Direct
212-849-7000 Main Office Number
212-849-7100 FAX
danielwiesner@quinnemanuel.com
www.quinnemanuel.com